PLSE (Pulse Biosciences) Cyclically Adjusted FCF per Share: $-1.40 (As of Mar. 2026)


PLSE Pulse Biosciences Inc PLSE
31 GF Score
Price $28.33
! 3 Warning Signs
View Full Analysis

What is Pulse Biosciences Cyclically Adjusted FCF per Share?

Pulse Biosciences PLSE +2.16% 31 Cyclically Adjusted FCF per Share is $-1.40 as of Mar. 2026. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Pulse Biosciences's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.215. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.40 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-01), Pulse Biosciences's current stock price is $28.33. Pulse Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-1.40. Pulse Biosciences's Cyclically Adjusted Price-to-FCF of today is .


Pulse Biosciences  (NAS:PLSE) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Pulse Biosciences Cyclically Adjusted FCF per Share Related Terms


Pulse Biosciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Pulse Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulse Biosciences Cyclically Adjusted FCF per Share Chart

Pulse Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.31 -1.37

Pulse Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.34 -1.36 -1.37 -1.37 -1.40

PLSE vs LMAT, XRAY, KMTS: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulse Biosciences Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's Cyclically Adjusted Price-to-FCF falls into.


PLSE
31GF Score
Pulse Biosciences Inc PLSE
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulse Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pulse Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.215/330.2130*330.2130
=-0.215

Current CPI (Mar. 2026) = 330.2130.

Pulse Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.232 241.018 -0.318
201609 -0.147 241.428 -0.201
201612 -0.171 241.432 -0.234
201703 -0.178 243.801 -0.241
201706 -0.083 244.955 -0.112
201709 -0.234 246.819 -0.313
201712 -0.235 246.524 -0.315
201803 -0.295 249.554 -0.390
201806 -0.341 251.989 -0.447
201809 -0.402 252.439 -0.526
201812 -0.353 251.233 -0.464
201903 -0.351 254.202 -0.456
201906 -0.463 256.143 -0.597
201909 -0.402 256.759 -0.517
201912 -0.433 256.974 -0.556
202003 -0.462 258.115 -0.591
202006 -0.359 257.797 -0.460
202009 -0.336 260.280 -0.426
202012 -0.370 260.474 -0.469
202103 -0.443 264.877 -0.552
202106 -0.611 271.696 -0.743
202109 -0.449 274.310 -0.541
202112 -0.425 278.802 -0.503
202203 -0.525 287.504 -0.603
202206 -0.401 296.311 -0.447
202209 -0.283 296.808 -0.315
202212 -0.211 296.797 -0.235
202303 -0.174 301.836 -0.190
202306 -0.200 305.109 -0.216
202309 -0.185 307.789 -0.198
202312 -0.120 306.746 -0.129
202403 -0.171 312.332 -0.181
202406 -0.147 314.175 -0.155
202409 -0.148 315.301 -0.155
202412 -0.148 315.605 -0.155
202503 -0.202 319.799 -0.209
202506 -0.192 322.561 -0.197
202509 -0.194 324.800 -0.197
202512 -0.219 324.054 -0.223
202603 -0.215 330.213 -0.215

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-1.40 mean?
Pulse Biosciences (PLSE) has a Cyclically Adjusted FCF per Share of $-1.40 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Pulse Biosciences and its competitors.
Is Pulse Biosciences' Cyclically Adjusted FCF per Share too high?
Pulse Biosciences' current Cyclically Adjusted FCF per Share is $-1.40. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' Cyclically Adjusted FCF per Share compare to LMAT and XRAY?
Pulse Biosciences' Cyclically Adjusted FCF per Share of $-1.40 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Pulse Biosciences and its competitors. Pulse Biosciences's current Cyclically Adjusted FCF per Share is $-1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current Cyclically Adjusted FCF per Share of $-1.40. The current Cyclically Adjusted FCF per Share is $-1.40. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current Cyclically Adjusted FCF per Share is $-1.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pulse Biosciences Business Description

Other Exchanges 6L8:Germany
Address 601 Brickell Key Drive, Suite 1080, Miami, FL, USA, 33131
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score

Get the complete analysis for PLSE

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.33
Price